The Magazine for Sleep Professionals
Thursday, April 30, 2026
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may […]
Home sleep tests (HSTs) have emerged as a convenient and cost-effective alternative to traditional in-lab polysomnography (PSG) for diagnosing sleep disorders, particularly obstructive sleep apnea (OSA). Over the years, HST technology has advanced significantly, leading to improvements in accuracy and reliability. In this article, I will explore the accuracy of […]
Neuroscientists have found the average person processes roughly 74 gigabytes of information every day.1 That is the equivalent of watching 16 movies, reading more than 200,000 words, or scrolling on TikTok for approximately 200 hours. In other words, we are inundated with information from every angle — social media, websites, […]
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]
Recent research has elevated the management of obesity in patients with sleep disorders to a prominent position in clinical practice. Obesity has been capturing attention across social media, mainstream news, and even in cultural references such as South Park specials and Jimmy Kimmel’s 2023 Oscars commentary. This heightened focus underscores […]
EnsoData, a leader in healthcare AI technology, is partnering with Advanced Brain Monitoring (ABM) to add position data captured by ABM’s Night Shift sleep positioner into the FDA-cleared EnsoSleep PPG home sleep test (HST). Adding positional data to EnsoSleep PPG offers providers accurate supine AHI severity insights, leading to better […]
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]
Takeda announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated […]
